Related Experiment Videos
Oral etoposide in lymphoma
1Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee 37203-1632, USA.
Drugs
|March 11, 2000
Summary
Oral etoposide demonstrates significant benefit for lymphoma patients, particularly those previously treated. Further research is needed to confirm optimal dosing and its role in previously untreated patients and HIV-related lymphomas.
Area of Science:
- Oncology
- Pharmacology
Background:
- Etoposide is a highly effective chemotherapeutic agent for lymphoma treatment.
- Oral etoposide has shown clear benefits in patients with previously treated lymphomas.
Purpose of the Study:
- To evaluate the efficacy and optimal use of oral etoposide in lymphoma therapy.
- To explore the role of oral etoposide in combination chemotherapy for various lymphoma types.
Main Methods:
- Review of existing studies on oral etoposide in lymphoma treatment.
- Analysis of preliminary data on combination chemotherapy regimens including oral etoposide.
Main Results:
- Oral etoposide is active and beneficial for previously treated lymphomas.
- Low daily doses (50-100 mg for 10-14 days) may be near optimal.
- Preliminary data suggest good activity and tolerability in elderly/unfit patients when combined with other agents.
Conclusions:
- Oral etoposide is a valuable option for lymphoma therapy, especially in previously treated cases.
- Further studies are warranted to establish optimal dosing and schedules for combination chemotherapy.
- Oral etoposide shows promise in elderly/unfit patients and HIV-related lymphomas.